Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, ...

Pharmaceuticals Industries is responding to the European Decision following its investigation into the company’s practices ...

TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European ... disagrees with the Commission’s legal theories ...

TEL AVIV – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced its decision to appeal against the European Commission's recent ruling related to its multiple sclerosis drug, COPAXONE®.

BRUSSELS -- The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its ...

Oct. 31 (UPI) --The European Commission fined Teva Pharmaceuticals $503 million for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.

The European Commission said the pharmaceutical ... and that it had supported the MS community since 1996. The EU Commission said Teva's actions may have prevented significant savings by countries ...